TY - JOUR
T1 - Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients
AU - García Morales, Olga Milena
AU - Cañas-Arboleda, Alejandra
AU - Rodríguez Malagón, María Nelcy
AU - Galindo Pedraza, Javier Leonardo
AU - Rodríguez Torres, Paola
AU - Avendaño Morales, Violeta Rosa
AU - González-Rangel, Andrés Leonardo
AU - Celis-Preciado, Carlos A
N1 - Copyright © 2024 García Morales, Cañas-Arboleda, Rodríguez Malagón, Galindo Pedraza, Rodríguez Torres, Avendaño Morales, González-Rangel and Celis-Preciado.
Publisher Copyright:
Copyright © 2024 García Morales, Cañas-Arboleda, Rodríguez Malagón, Galindo Pedraza, Rodríguez Torres, Avendaño Morales, González-Rangel and Celis-Preciado.
PY - 2024
Y1 - 2024
N2 - Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death among adults. In 2019, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy incorporated blood eosinophils as a biomarker to identify patients at increased risk of exacerbations which, with the history of exacerbations during the previous year, allows identification of patients who would benefit from anti-inflammatory treatment to reduce the risk of future exacerbations. The aim of this study was to describe demographic and clinical characteristics, eosinophil counts, and exacerbations in a cohort of COPD patients stratified by clinical phenotypes (non-exacerbator, frequent exacerbator, asthma-COPD overlap) in a Colombian cohort at 2600 meters above sea level. Methods: A descriptive analysis of a historical cohort of patients with a confirmed diagnosis of moderate to severe COPD (FEV
1/FVC < 0.7 and at least one risk factor for COPD) from two specialized centers with comprehensive disease management programs was performed from January 2015 to March 2019. Data were extracted from medical records 1 year before and after the index date. Results: 200 patients were included (GOLD B: 156, GOLD E: 44; 2023 GOLD classification); mean age was 77.9 (SD 7.9) years; 48% were women, and 52% had biomass exposure as a COPD risk factor. The mean FEV
1/FVC was 53.4% (SD 9.8), with an FEV
1 of 52.7% (20.7). No differences were observed between clinical phenotypes in terms of airflow limitation. The geometric mean of absolute blood eosinophils was 197.58 (SD 2.09) cells/μL (range 0 to 3,020). Mean blood eosinophil count was higher in patients with smoking history and frequent exacerbators. At least one moderate and one severe exacerbation occurred in the previous year in 44 and 8% of patients, respectively; during the follow-up year 152 exacerbations were registered, 122 (80%) moderate and 30 (20%) severe. The highest rate of exacerbations in the follow-up year occurred in the subgroup of patients with the frequent exacerbator phenotype and eosinophils ≥300 cells/μL. Discussion: In this cohort, the frequency of biomass exposure as a risk factor is considerable. High blood eosinophil count was related to smoking, and to the frequent exacerbator phenotype.
AB - Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death among adults. In 2019, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy incorporated blood eosinophils as a biomarker to identify patients at increased risk of exacerbations which, with the history of exacerbations during the previous year, allows identification of patients who would benefit from anti-inflammatory treatment to reduce the risk of future exacerbations. The aim of this study was to describe demographic and clinical characteristics, eosinophil counts, and exacerbations in a cohort of COPD patients stratified by clinical phenotypes (non-exacerbator, frequent exacerbator, asthma-COPD overlap) in a Colombian cohort at 2600 meters above sea level. Methods: A descriptive analysis of a historical cohort of patients with a confirmed diagnosis of moderate to severe COPD (FEV
1/FVC < 0.7 and at least one risk factor for COPD) from two specialized centers with comprehensive disease management programs was performed from January 2015 to March 2019. Data were extracted from medical records 1 year before and after the index date. Results: 200 patients were included (GOLD B: 156, GOLD E: 44; 2023 GOLD classification); mean age was 77.9 (SD 7.9) years; 48% were women, and 52% had biomass exposure as a COPD risk factor. The mean FEV
1/FVC was 53.4% (SD 9.8), with an FEV
1 of 52.7% (20.7). No differences were observed between clinical phenotypes in terms of airflow limitation. The geometric mean of absolute blood eosinophils was 197.58 (SD 2.09) cells/μL (range 0 to 3,020). Mean blood eosinophil count was higher in patients with smoking history and frequent exacerbators. At least one moderate and one severe exacerbation occurred in the previous year in 44 and 8% of patients, respectively; during the follow-up year 152 exacerbations were registered, 122 (80%) moderate and 30 (20%) severe. The highest rate of exacerbations in the follow-up year occurred in the subgroup of patients with the frequent exacerbator phenotype and eosinophils ≥300 cells/μL. Discussion: In this cohort, the frequency of biomass exposure as a risk factor is considerable. High blood eosinophil count was related to smoking, and to the frequent exacerbator phenotype.
KW - Colombia
KW - biomass
KW - chronic obstructive pulmonary disease
KW - eosinophils
KW - phenotype
KW - smoking
UR - http://www.scopus.com/inward/record.url?scp=85194238293&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/937bcba9-2366-3cab-a25e-f25699514136/
U2 - 10.3389/fmed.2024.1321371
DO - 10.3389/fmed.2024.1321371
M3 - Artículo
C2 - 38803343
SN - 2296-858X
VL - 11
SP - 1321371
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 1321371
ER -